Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067155 | 1.00 | KMT2A (0.33) | KMT2AMEN1OPRK1 | |
| SCHEMBL20000862 | 1.00 | KMT2A (0.33) | KMT2AMEN1OPRK1 | |
| SCHEMBL20000861 | 0.69 | NOS3 (0.33) | — | |
| SCHEMBL20067157 | 0.69 | NOS3 (0.33) | — | |
| SCHEMBL20000858 | 0.69 | NOS3 (0.33) | — | |
| SCHEMBL20000850 | 0.68 | SORT1 (0.38) | — | |
| SCHEMBL20067154 | 0.68 | SORT1 (0.38) | — | |
| SCHEMBL20067153 | 0.68 | SORT1 (0.38) | — | |
| SCHEMBL20000842 | 0.64 | — | — | |
| SCHEMBL20000843 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344002-B2 | Compositions and methods for treating metabolic disorders | NUSIRT SCIENCES, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. | 2018-04-19 | — | — | US | disclosed |
| WO-2018058109-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344002-B2 | Compositions and methods for treating metabolic disorders | LIPC, PC, PNLIP | KMT2A 2186/4885MEN1 1256/4885OPRK1 4688/4885 |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | LIPC, PC, PNLIP | KMT2A 2186/4885MEN1 1256/4885OPRK1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.